Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients

Cytokine

Volumn 10, Issue 2, 1998, Pages 132-139

  Provinciali, Mauro ^a   Di Stefano, Giuseppina ^a   Stronati, Stefania ^a   Fabris, Nicola ^b  

^a INRCA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Aging; Cancer; IL 2 pulse; LAK cells

Indexed keywords

CD16 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; TRANSFERRIN RECEPTOR;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER; CANCER PATIENT; CELL CULTURE; CELL CYCLE PHASE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TOXICITY; ELDERLY CARE; FEMALE; HUMAN; HUMAN CELL; LYMPHOKINE ACTIVATED KILLER CELL; MALE; MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL;

EID: 0032007311     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1997.0265     Document Type: Article

References (18)

1. 1. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettighausen JE, Matori YL, Skibberg JM, Shiloni E, Vetto JV, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant IL-2 to patients with metastatic cancer. N Engl J Med 313:1485-1492.
2. 2. Siegel JP, Puri RK (1991) Interleukin-2 toxicity. J Clin Oncol 9:694-699.
3. 3. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, White DE, Steinberg SM (1993) Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85:622-632.
4. 4. Owen-Schuab LB, Loudon WG, Yagita M, Grimm EA (1988) Functional differentiation of human lymphokine-activated killing (LAK) is distinct from expansion and involves dissimilar interleukin-2 receptors. Cell Immunol 111:235-246.
5. 5. Horton SA, Oldham RK, Yannelli JR (1990) Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin-2. Cancer Res 50:1686-1692.
6. 6. Palmer PA, Scharenberg JGM, Von Blomberg BME, Stam AGM, Meijer CJLM, Roest GJ, Franks CR, Scheper RJ (1994) Persistent augmentation of natural-killer and T-cell-mediated cytotoxicity in peripheral blood mononuclear cells pulsed in vitro with high-dose recombinant interleukin-2 prior to culturing with a low maintenance dose. Cancer Immunol Immunother 39:34-40.
7. 7. Buer J, Hilse R, Dallmann I, Grosse J, Kirchner H, Zorn U, Lopez Hanninen E, Franzke A, Duensing S, Poliwoda H, Atzpodien J (1995) Lymphocyte-conditioned medium in combination with interleukin-2 effectively induces antitumour autoimunity by adoptive transfer of short activated killer (SHAK) cells. Cytokines Mol Ther 1:39-46.
8. 8. Wigginton JM, Komschlies KL, Bach TC, Franco JL, Brunda MJ, Wiltrout RH (1996) Administration of interleukin 12 with pulse interleukin 2 and rapid and complete eradication of murine renal carcinoma. J Natl Cancer Inst 88:38-43.
9. 9. Gillis S, Kozak R, Durante M, Weksler ME (1981) Decreased production of and response to T cell growth factor by lymphocytes from aged humans. J Clin Invest 67:837-842.
10. 10. Balducci L, Mowrey K, Parker M (1992) Pharmacology of antineoplastic agents in older patients. In: Balducci L, Lyman GH and Ershler WB (eds), Geriatric Oncology, Lippincott Company, Philadelphia, pp. 169-180.
11. 11. Provinciali M, Di Stefano G, Fabris N (1995) Evaluation of lymphokine-activated killer cell development in young and old health humans. Nat Immun 14:134-144.
12. 12. Kawakami K, Bloom ET (1987) Lymphokine-activated killer cells and aging in mice: Significance for defining the precursor cell. Mech Ageing Dev 41:229-240.
13. 13. Robertson MJ, Caligiuri MA, Manley TJ, Levine H, Ritz J (1990) Human natural killer cell adhesion molecules. J Immunol 145:3194-3201.
14. 14. Vaux DL (1993) Toward an understanding of the molecular mechanisms of phisiological cell death. Proc Natl Acad Sci USA 90:786-789.
15. 15. Provinciali M, Di Stefano G, Fabris N (1992) Optimization of cytotoxic assay by target cell retention of the fluorescent dye carboxyfluorescein diacetate (CFDA) and comparison with conventional Cr51-release assay. J Immunol Methods 155:19-24.
16. 16. Bryant J, Day R, Whiteside T, Herberman RB (1992) Calculation of lytic units for the expression of cell-mediated cytotoxicity. J Immunol Methods 146:91-103.
17. 17. Fried J, Perez AG, Clarkson BD (1978) Rapid hypotonic method for flow cytofluorimetry of monolayer cell cultures. J Histochem Cytochem 26:921-923.
18. 18. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271-279.